.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Verteporfin - Generic Drug Details

« Back to Dashboard
Verteporfin is the generic ingredient in one branded drug marketed by Valeant Luxembourg and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

This ingredient has forty-two patent family members in twenty-three countries.

There is one drug master file entry for verteporfin. Two suppliers are listed for this compound.

Summary for Generic Name: verteporfin

Tradenames:1
Patents:3
Applicants:1
NDAs:1
Drug Master File Entries: see list1
Suppliers / Packaging: see list2
Drug Prices:see low prices

Pharmacology for Ingredient: verteporfin

Drug ClassPhotoenhancer
Mechanism of ActionPhotoabsorption
Physiological EffectPhotosensitizing Activity
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Luxembourg
VISUDYNE
verteporfin
INJECTABLE;INJECTION021119-001Apr 12, 2000RXYes5,756,541► subscribe ► subscribe
Valeant Luxembourg
VISUDYNE
verteporfin
INJECTABLE;INJECTION021119-001Apr 12, 2000RXYes5,707,608► subscribe ► subscribe
Valeant Luxembourg
VISUDYNE
verteporfin
INJECTABLE;INJECTION021119-001Apr 12, 2000RXYes5,798,349► subscribe ► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: verteporfin

These historical archives are available as an add-on to one-year subscriptions.
See the Subscription Options for more information.

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Luxembourg
VISUDYNE
verteporfin
INJECTABLE;INJECTION021119-001Apr 12, 20005,798,349► subscribe
Valeant Luxembourg
VISUDYNE
verteporfin
INJECTABLE;INJECTION021119-001Apr 12, 20005,707,608► subscribe
Valeant Luxembourg
VISUDYNE
verteporfin
INJECTABLE;INJECTION021119-001Apr 12, 20005,756,541► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: verteporfin

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,910,510 Vision through photodynamic therapy of the eye► subscribe
5,707,986 Angiographic method using green porphyrins in primate eyes► subscribe
6,610,679 Use of green porphyrins to treat neovasculature in the eye► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: verteporfin

Country Document Number Estimated Expiration
Argentina042931► subscribe
World Intellectual Property Organization (WIPO)9704746► subscribe
Portugal843547► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: VERTEPORFIN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB01/005United Kingdom► subscribePRODUCT NAME: VERTEPORFIN OPTIONALLY IN THE FORM OF A SALT THEREOF; REGISTERED: UK EU/1/00/140/001 20000727
01C/010Belgium► subscribePRODUCT NAME: VERTEPORFIN; NAT. REGISTRATION NO./DATE: EU/1/00/140/001 20000727; FIRST REGISTRATION: CH 55269 19991215
2001Austria► subscribePRODUCT NAME: VERTEPORFIN; REGISTRATION NO/DATE: EU/1/00/140/001 20000727
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc